FGF binding by extracellular matrix components of Wharton's jelly

• Authors: Andrzej Malkowski , Krzysztof Sobolewski , Stefan Jaworski , Edward Bankowski
• Languages of publication: EN

Abstracts

EN

Our earlier paper has reported that Wharton's jelly is a reservoir of several peptide growth factors, including acidic and basic fibroblast growth factors (aFGF and bFGF, respectively). Both can be extracted by buffered salts solutions in the form of high molecular mass complexes, probably with a component(s) of the extracellular matrix. Both aFGF and bFGF from such extracts hardly penetrate 10% polyacrylamide gels during electrophoresis. Pre-treatment of Wharton's jelly with hyaluronidase slightly increased the extractability of aFGF, but did not affect the extractability of bFGF. In contrast, the pre-treatment of tissue homogenate with bacterial collagenase (2000 U/ml, 37°C, 18 h) increased the extractability of bFGF. The presence of β-mercaptoethanol in the extracting solutions increased the extractability of both FGFs, but did not release FGFs in their free form, despite reducing the molecular mass of the FGF-containing complexes. We conclude that both aFGF and bFGF are bound through disulphide bonds to a protein component of Wharton's jelly. We propose that ground substance composed mainly of collagen fibrils and hyaluronate molecules, which surrounds the cells of Wharton's jelly, prevents the access of the extracting solution to aFGF and bFGF. Although hyaluronate and collagen do not bind aFGF or bFGF directly, they may constitute a barrier which prevents the dispersion of FGFs in Wharton's jelly. Thus, the high concentration of FGFs around the cells of Wharton's jelly may facilitate the interaction of these factors with membrane receptors, thereby resulting in stimulation of cell division and differentiation, as well as of the synthesis of extracellular matrix components.

Keywords

EN

umbilical cord; fibroblast growth factor; metalloproteinases

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2007
• Volume: 54
• Issue: 2
• Pages: 357-363

Dates

published

2007

received

2006-11-14

revised

2007-03-27

accepted

2007-05-23

(unknown)

2007-06-12

Contributors

author

Andrzej Malkowski

• Department of Medical Biochemistry, Medical Academy of Bialystok, Białystok, Poland

author

Krzysztof Sobolewski

• Department of Medical Biochemistry, Medical Academy of Bialystok, Białystok, Poland

author

Stefan Jaworski

• Department of Gynaecology, Medical Academy of Bialystok, Białystok, Poland

author

Edward Bankowski

• Department of Medical Biochemistry, Medical Academy of Bialystok, Białystok, Poland

References

• Bańkowski E, Sobolewski K, Romanowicz L, Chyczewski L, Jaworski S (1996) Collagen and glycosaminoglycans of Wharton's jelly and their alterations in EPH-gestosis. Eur J Obstet Gynecol Reprod Biol 66: 109-117.
• Carey DJ (1997) Syndecans: multifunctional cell-surface co-receptors. Biochem J 327: 1-16.
• Edmondson SR, Thumiger SP, Werther GA, Wraight CJ (2003) Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr Rev 24: 737-764.
• Franc S, Rousseau JC, Garrone R, van der Rest M, Moradi-Ameli M (1998) Microfibrilar composition of umbilical cord matrix: characterization of fibrillin, collagen VI and intact collagen V. Placenta 19: 95-104.
• Gallagher JT (1996) Heparan sulphate proteoglycans. The control of cell growth. In Extracellular matrix 2 (Comper WD, eds) pp 230-245. Amsterdam: Harwood Academic Publishers GmbH.
• Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL (1985) Biochemical and immunological characterization of secreted forms of human neutrophil gelatinase. J Biol Chem 260: 2493-2500.
• Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M (1986) Analysis of serum insulin insulin-like growth factor binding proteins using Western blotting; use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 154: 138-143.
• Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-652.
• Jackson RL, Busch SJ, Cardin AD (1991) Glycosaminoglycans: molecular properties, protein interaction, and role in physiological processes. Physiol Rev 71: 481-525.
• Kobayashi K, Kubota T, Aso T (1998) Study on myofibroblasts differentiation in the stroma cells of Wharton's jelly: expression and localization of α-smooth muscle actin. Early Hum Dev 51: 223-233.
• Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
• Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, Xie QD, Huang TH (2005) Human umbilical cord Wharton's jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J 118: 1987-1993.
• Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, Helwig B, Beerenstrauch M, Abou-Easa K, Hildreth T, Troyer D, Medicetty S (2003) Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21: 50-60.
• Ornitz DM, Itoh N (2001) Fibroblast growth factors. Genome Biology 2: reviews3005.1-12.
• Overall CM (2002) Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 22: 51-86.
• Raio L, Cromi A, Ghezzi F, Passi A, Karousou E, Viola M, Vigetti D, De Luca G, Bolis P (2005) Hyaluronan content of Wharton's jelly in healthy and Down syndrome fetuses. Matrix Biol 24: 166-174.
• Shalitin N, Schlesinger H, Levy MJ, Kessler E, Kessler-Icekson G (2003) Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for coregulation with type I collagen. J Cell Biochem 90: 397-407.
• Sobolewski K, Bańkowski E, Chyczewski L, Jaworski S (1997) Collagen and glycosaminoglycans of Wharton's jelly. Biol Neonate 71: 11-21.
• Sobolewski K, Małkowski A, Bańkowski E, Jaworski S (2005) Wharton's jelly as a reservoir of peptide growth factors. Placenta 26: 747-752.
• Taipale J, Keski-Oja J (1997) Growth factors in the extracellular matrix. FASEB J 11: 51-59.
• Takechi K, Kuwabara Y, Mizuno M (1993) Ultrastructural and immunohistochemical studies of Wharton's of jelly umbilical cord cells. Placenta 14: 235-245.
• Tanaka Y, Kimata K, Adams DH, Eto S (1998) Modulation of cytokine function by heparin sulfate proteoglycans: sophisticated models for the regulation of cellular responses to cytokines. Proc Assoc Am Physicians 110: 118-125.
• Wang HS, Hung CS, Peng ST, Huang CC, Wei HM Guo YJ, Fu YS, Lai MC, Chen CC (2004) Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 22: 1330-1337.
• Weiss ML, Mitchell KE, Hix JE, Medicetty S, El-Zarkouny SZ, Grieger D, Troyer DL (2003) Transplantation of porcine umbilical cord matrix cells into the brain. Exp Neurol 182: 288-299.
• Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, Luo Y, Rao MS, Velagaleti G, Troyer D (2006) Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24: 781-792.
• Yu C, Wang F, Jin C, Huang X, Miller DL, Basilico C, McKeehan WL (2003) Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogensesis. Am J Pathol 163: 1653-1662.